Drug Shortage Report for TEVA-SALBUTAMOL HFA
Report ID | 105599 |
Drug Identification Number | 02326450 |
Brand name | TEVA-SALBUTAMOL HFA |
Common or Proper name | SALBUTAMOL 100MCG HFA INHALER |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | SALBUTAMOL |
Strength(s) | 100MCG |
Dosage form(s) | METERED-DOSE AEROSOL |
Route of administration | INHALATION |
Packaging size | 200 dose |
ATC code | R03AC |
ATC description | ADRENERGICS, INHALANTS |
Reason for shortage | Other (Please describe in comments) |
Anticipated start date | |
Actual start date | 2020-02-07 |
Estimated end date | 2020-07-31 |
Actual end date | 2020-07-29 |
Shortage status | Resolved |
Updated date | 2020-07-30 |
Company comments | Teva Allocating to 70% of the generic market. Increased demand experienced. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2020-02-07 | English | Compare |